Stroke due to spontaneous intracerebral haemorrhage

When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 12 Feb 2025
Last updated: 15 Mar 2024

Summary

Definition

History and exam

Key diagnostic factors

  • unilateral weakness or paralysis in the face, arm, or leg
  • sensory loss (numbness)
  • dysphasia
  • dysarthria
  • visual disturbance
  • photophobia
  • headache
  • ataxia
  • risk factors
Full details

Other diagnostic factors

  • vertigo
  • nausea/vomiting
  • decreased level of consciousness/coma
  • confusion
  • gaze paresis
Full details

Risk factors

  • hypertension
  • older age
  • male sex
  • Asian, black and/or Latino/Hispanic
  • heavy alcohol use
  • illicit sympathomimetic drugs
  • family history of intracerebral haemorrhage
  • haemophilia
  • cerebral amyloid angiopathy
  • sickle cell disease
  • autosomal dominant mutations in the COL4A1 gene
  • hereditary haemorrhagic telangiectasia
  • autosomal dominant mutations in the KRIT1 gene, CCM2 gene, or PDCD10 gene
  • anticoagulation
  • vascular malformations
  • Moyamoya disease
  • pregnancy
  • smoking
  • non-steroidal anti-inflammatories (NSAIDs)
  • obstructive sleep apnoea
  • diabetes mellitus
  • sympathomimetic medications
  • cerebral vasculitis
  • thrombocytopenia
  • leukaemia
Full details

Diagnostic investigations

1st investigations to order

  • non-contrast CT head
  • serum glucose
  • serum electrolytes
  • serum urea and creatinine
  • liver function tests
  • FBC
  • clotting screen
  • ECG
Full details

Investigations to consider

  • serum toxicology screen
  • CT angiography (CTA) or magnetic resonance angiography (MRA) head
  • CT venography or magnetic resonance venography head
  • Intra-arterial cerebral angiography
Full details

Treatment algorithm

INITIAL

suspected intracerebral haemorrhage

ACUTE

confirmed intracerebral haemorrhage

Contributors

Expert advisers

Matthew Jones, MD, FRCP

Consultant Neurologist

Manchester Centre for Clinical Neurosciences

Northern Care Alliance

Honorary Senior Lecturer

University of Manchester

Manchester

UK

Disclosures

MJ is the chair of the Association of British Neurologists Education Committee (unpaid position). MJ is a faculty member of an MRCP revision course. MJ has received honoraria from Eisai for educational talks.

Acknowledgements

BMJ Best Practice would like to gratefully acknowledge the previous expert contributors, whose work has been retained in parts of the content:

Fernando D. Goldenberg, MD

Clinical Associate of Neurology

Medical Director, Neuroscience ICU

Director, Neurocritical Care Education

Co-Director, Stroke Center

University of Chicago

Chicago

IL

Raisa C. Martinez, MD

Neurocritical Care Fellow

Department of Neurology

University of Chicago

Chicago

IL

Disclosures

FDG and RCM declare that they have no competing interests.

Peer reviewers

David Werring, FRCP, PhD, FESO

Professor of Clinical Neurology

Head of Research Department, Brain Repair and Rehabilitation

UCL Institute of Neurology

Honorary Consultant Neurologist

National Hospital for Neurology and Neurosurgery

University College Hospitals NHS Foundation Trust

North Thames Clinical Research Specialty Lead for Stroke

NIHR Clinical Research Network

London

UK

Disclosures

DW has received honoraria (speaking) from Bayer 2016, 2017, 2018 (talks or debates on intracerebral haemorrhage, atrial fibrillation, dementia) and honoraria (chairing) from Portola and Bayer 2019. DW has received consultancy fees from Bayer (2017; embolic stroke of undetermined source), JFB consulting (2018; PCSK9 inhibitors in stroke), Alnylam (2019; cerebral amyloid angiopathy), Portola (2019, 2020; andexanet alpha). JW was UCL Principle Investigator for NIHR clinical trials NAVIGATE-ESUS (Bayer, 2016-19), B2341002 (Pfizer 2014-2016), Action-2 (Biogen, 2016-19); Chief Investigator for OPTIMAS; steering committee and co-investigator for RESTART, TICH-2.

Editors

Helena Delgado-Cohen

Section Editor, BMJ Best Practice

Disclosures

HDC declares that she has no competing interests.

Tannaz Aliabadi-Oglesby

Lead Section Editor, BMJ Best Practice

Disclosures

TAO declares that she has no competing interests.

Julie Costello

Comorbidities Editor, BMJ Best Practice

Disclosures

JC declares that she has no competing interests.

Adam Mitchell

Drug Editor, BMJ Best Practice

Disclosures

AM declares that he has no competing interests.

  • Stroke due to spontaneous intracerebral haemorrhage images
  • Differentials

    • Ischaemic stroke
    • Hypertensive encephalopathy
    • Hypoglycaemia
    More Differentials
  • Guidelines

    • National clinical guideline for stroke for the United Kingdom and Ireland
    • Stroke and transient ischaemic attack in over 16s: diagnosis and initial management
    More Guidelines
  • Calculators

    NIH Stroke Score

    Glasgow Coma Scale

    More Calculators
  • Videos

    Venepuncture and phlebotomy animated demonstration

    How to perform an ECG animated demonstration

    More videos
  • Patient information

    Stroke: treatment

    Questions to ask your doctor if you've had a stroke

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer